Evidence map›Paper›PMID 41826608›Full record

ArticleArchives of pharmacal research2026

Homoharringtonine inhibits growth and migration in non-small cell lung cancer via PDIA4-mediated modulation of autophagy and EMT.

Xiaoyu Ma, Panpan Lei, Bingxi Ren, Sifan Xie, Yuxiu Zhang, Yuanji Wang, Weina Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of pharmacal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoyu Ma *School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China.
Panpan Lei *School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China.
Bingxi Ren *School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China.
Sifan XieSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China.
Yuxiu ZhangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China.
Yuanji WangDepartment of Pharmacy, The First Affiliated Hospital of Northwest University, Xi'an, 710002, China.
Weina MaSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China. maweina2015@xjtu.edu.cn.ORCID http://orcid.org/0000-0002-6077-904X

Funding

National Natural Science Foundation of China U24A20786Natural Science Basic Research Program of Shaanxi Province 2025JC-YBMS-957
6 · The paper itself

Abstract

Protein disulfide isomerase A4 (PDIA4) is overexpressed in non-small cell lung cancer (NSCLC) and is associated with poor prognosis. This study demonstrates that elevated PDIA4 expression promotes NSCLC progression, whereas its knockdown inhibits disease advancement, establishing PDIA4 as an oncogenic driver and potential biomarker. Homoharringtonine (HHT), a natural alkaloid with broad-spectrum antitumor activity, exhibits efficacy against NSCLC, but its underlying mechanism remains unclear. In this study, HHT markedly suppresses NSCLC growth and migration in a PDIA4-dependent manner. Mechanistically, HHT initiates autophagy by regulating the AMPK/mTOR signaling pathway, while blocking autophagic flux, leading to autophagosome accumulation and consequent inhibition of NSCLC growth. Additionally, HHT inhibits NSCLC migration by modulating epithelial-mesenchymal transition (EMT) signaling. These findings highlight PDIA4 as a critical mediator of HHT efficacy against NSCLC, provide novel insights into PDIA4-associated therapy, and support the translational potential of HHT in NSCLC treatment.

Indexed as

Antineoplastic Agents, PhytogenicAutophagyCarcinoma, Non-Small-Cell LungEpithelial-Mesenchymal TransitionHomoharringtonineLung NeoplasmsProtein Disulfide-IsomerasesCell MovementCell ProliferationDose-Response Relationship, DrugHumansProcollagen-Proline DioxygenaseSignal TransductionAntineoplastic Agents, PhytogenicHomoharringtonineP4HB protein, humanProcollagen-Proline DioxygenaseProtein Disulfide-IsomerasesAutophagyEpithelial-mesenchymal transitionHomoharringtonineNon-small cell lung cancerProtein disulfide isomerase A4

Identifiers

PMID41826608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.